Tanachat Nilanon

Recent advances in miniaturization and sensor technology have greatly improved availability and affordability of consumer wearable activity trackers. Although these devices produce measurements that are still less accurate than those obtained in a controlled environment of a clinic, they can provide real-world outpatient activity data that can be useful to inform physicians of patients’ physical activity (PA) level.

Accurate assessment of an oncology patient’s performance status (PS) is paramount for informing therapeutic decision making, whether it be to predict response and tolerability to treatment or determine eligibility for clinical trials. However, the 2 conventional scales used to measure PS—the Karnofsky Performance Status (KPS) scale and the Eastern Cooperative Oncology Group (ECOG) ranking—are observational and thus inherently limited in their precision.